您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (3): 77-80.doi: 10.6040/j.issn.1671-7554.0.2015.929

• • 上一篇    下一篇

mir-99a的表达与上皮性卵巢癌患者预后的关系

徐志宏1,吴小华2,姚铁柱3,王晓翔1,段晓阳1,史健1   

  1. 1.河北医科大学第四医院肿瘤内科, 河北 石家庄 050011;2.白求恩国际和平医院妇产科, 河北 石家庄050000;3.河北医科大学第四医院心内科, 河北 石家庄 050011
  • 收稿日期:2015-09-28 出版日期:2016-03-10 发布日期:2016-03-10
  • 通讯作者: 姚铁柱. E-mail:13733315579@163.com E-mail:13733315579@163.com

Relationship between mir-99a expression and prognosis of epithelial ovarian cancer

XU Zhihong1, WU Xiaohua2, YAO Tiezhu3, WANG Xiaoxiang1, DUAN Xiaoyang1, SHI Jian1   

  1. 1. Department of Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China;
    2. Department of Obstetrics and Gynaecology, Bethune International Peace Hospital, Shijiazhuang 050000, Hebei, China;
    3. Department of Cardiology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2015-09-28 Online:2016-03-10 Published:2016-03-10

PDF (PC)

396

摘要： 目的 探讨mir-99a在上皮性卵巢癌(EOC)患者中的表达与临床病理特征及预后的关系。 方法 采用实时荧光定量PCR(qRT-PCR)法检测137例EOC患者组织中mir-99a的表达水平,分析mir-99a表达与卵巢癌患者的临床病理资料的相关性。采用Kaplan-Meier法进行生存分析并绘制生存曲线,生存因素采用log-rank检验。 结果 EOC患者组织中mir-99a的表达较癌旁正常组织降低(P<0.001)。mir-99a的低表达与高组织学分级(P=0.027)、淋巴结转移(P=0.001)、腹膜转移(P<0.001)和较高的FIGO分期(P<0.001)有关。Kaplan-Meier分析与log-rank检验结果显示,mir-99a的低表达与EOC患者生存期短有关(对数秩检验,P=0.005)。多因素分析结果显示,mir-99a表达是患者总体生存的独立预测因子(HR为2.368,95%CI:1.621,10.925, P=0.016)。 结论 mir-99a的表达是上皮性卵巢癌患者独立的预后因素,mir-99a可能成为临床实践中一项新的诊断和预后标志物。

关键词: mir-99a, 上皮性卵巢癌, 预后, 临床病理学

Abstract: Objective To investigate the mir-99a expression in epithelial ovarian cancer(EOC), and its relationship with the clinicopathological features and prognosis. Methods The mir-99a expression in 137 cases of EOC tissues was detected with qRT-PCR assay. The correlation between mir-99a expression and clinicopathological features of EOC were analyzed. Survival curves for patients with different mir-99a expressions were plotted using the Kaplan-Meier method and compared using the log-rank test. Results The mir-99a expression reduced significantly in EOC tissues compared with that in adjacent normal tissues(P<0.001). Low mir-99a expression was significantly correlated with higher histological grade(P=0.027), lymph node metastasis(P=0.001), peritoneal metastasis(P<0.001), and higher FIGO stage(P<0.001). Kaplan-Meier analysis with log-rank test revealed that low mir-99a expression was correlated with short survival time of patients with EOC(log-rank test, P=0.005). Multivariate analysis showed that mir-99a expression was an independent prognostic factor for the overall survival(HR: 2.368, 95%CI: 1.621-10.925, P=0.016). Conclusion The mir-99a expression is an independent prognostic factor of patients with EOC. It can serve as a diagnostic and prognostic marker in clinical practice.

Key words: Epithelial ovarian cancer, Prognosis, mir-99a, Clinical pathology

中图分类号: 

  • R737.31
[1] Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, et al. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran[J]. Electron Physician, 2015, 7(6): 1399-1406. doi: 10.14661/1399. eCollection 2015.
[2] Cheng W, Liu J, Yoshida H, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract[J]. Nature medicine, 2005, 11(5): 531-537.
[3] Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer[J]. Hormones Cancer, 2010, 1(6): 277-290.
[4] Jönsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex steroid hormone receptor expression affects ovarian cancer survival[J]. Transl Oncol, 2015, 8(5): 424-433.
[5] Jiang H, Qu L, Wang Y, et al. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells[J]. Biomedicine Pharmacotherapy, 2014, 68(2): 163-169.
[6] Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer[J]. J Pathol, 2011, 223(2): 102-115.
[7] Bushati N, Cohen SM. microRNA functions[J]. Annu Rev Cell Dev Biol, 2007, 23:175-205.
[8] Calin GA, Croce CM. MicroRNA signatures in human cancers[J]. Nature reviews Cancer, 2006, 6(11): 857-866.
[9] 何玲, 林功标, 程金妹. MicroRNA在头颈肿瘤的研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 2: 170-173.
[10] Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis[J]. Cancer Res, 2007, 67(10): 4553-4555.
[11] Croce CM, Calin GA. miRNAs, cancer, and stem cell division[J]. Cell, 2005, 122(1): 6-7.
[12] Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue[J]. Cancer Genomics Proteomics, 2009, 6(5): 281-295.
[13] Faruq O, Vecchione A. microRNA: Diagnostic Perspective[J]. Front Med, 2015, 2: 51. doi: 10.3389/fmed.2015.00051. eCollection 2015.
[14] Chen Z, Jin Y, Yu D, et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma[J]. Oral Oncol, 2012, 48(8): 686-691.
[15] Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma[J]. J Biol Chem, 2011, 286(42): 36677-36685.
[16] Sun D, Lee YS, Malhotra A, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation[J]. Cancer Res, 2011, 71(4): 1313-1324.
[17] Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer[J]. Cancer Res, 2009, 69(21): 8472-8481.
[18] Torres A, Torres K, Pesci A, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma[J]. BMC Cancer, 2012, 12: 369. doi: 10.1186/1471-2407-12-369
[19] Sun J, Chen Z, Tan X, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma[J]. Med Oncol, 2013, 30(1): 411. doi: 10.1007/s12032-012-0411-9. Epub 2013 Jan 5.
[20] Cui L, Zhou H, Zhao H, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma[J]. BMC Cancer, 2012, 12: 546. doi: 10.1186/1471-2407-12-546.
[1] 李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2] 刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3] 王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4] 贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5] 杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6] 杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7] 刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[8] 陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[9] 郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[10] 魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[11] 刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[12] 杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[13] 刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[14] 宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[15] 刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发